Business
Vector Pharma Middle East Distribution Agreement
Vector Pharma Middle East Distribution Agreement.
About this update from Renalytix Plc
[{"type":"text","content":"\n\n \nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nMiddle East Distribution Agreement with Vector Pharma\n \nCommercial availability of kidneyintelX.dkd™ expanded to an estimated\n4 million DKD Patients in the Middle East\n \nDistribution agreement opens kidneyintelX.dkd testing to address early-stage kidney disease in region with one of the highest incidence rates for type 2 diabetes globally\n \nLONDON and SALT LAKE CITY, July 21, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces opening the commercial availability of kidneyintelX.dkd™ testing in Saudi Arabia, Bahrain, Qatar, Oman, Kuwait, and United Arab Emirates through a distribution agreement with Vector Pharma. Following the recent announcement of FDA marketing authorization for kidneyintelX.dkd, Renalytix will take advantage of select opportunities to expand testing services outside the US market with qualified distribution partners.\n \nIn the six markets of the Gulf Cooperation Council (GCC), the International Diabetes Federation (IDF) has reported high prevalence rates of diabetes, with more than 20% of the population being diabetic and more than 15% being pre-diabetic in most GCC countries. These are among the highest reported incidence rates for diabetes globally1. Chronic kidney disease (CKD) is a significant complication of type 2 diabetes (T2D) in this region. An estimated 58% of individuals with T2D develop CKD, which concurrently increases the risk of heart failure and myocardial infarction2.\n \nThe agreement with Vector Pharma brings established distribution and market access capabilities with a strong GCC footprint. Vector Pharma will initially focus on building awareness and driving adoption to achieve specified annual sales targets by territory with kidneyintelX.dkd.\n \n\"As in the United States, patient care for early-stage diabetes and kidney disease is in the hands of primary care clinicians,\" said Tom McLain, President, Renalytix. \"Traditional laboratory distributors do not call on primary care practices. Our partnership with Vector Pharma, a pharmaceutical distributor with proven access and contacts in primary care, will accelerate efforts to introduce kidneyintelX.dkd and expand test adoption.\"\n \nVector Pharma Chief Executive Officer, Patrick Jordan, co...